AI Generated Image
Silence Therapeutics blood cancer drug delivers strong results
STAT • • business
Key Points:
- Silence Therapeutics' experimental drug, divesiran, stabilized red blood cell levels in patients with polycythemia vera, a rare blood cancer, during a Phase 2 trial.
- Polycythemia vera causes excessive red blood cell production, increasing risks of blood clots, bleeding, and other cancers.
- In the 48-patient trial, 88% of those treated with divesiran every six or 12 weeks showed clinical response, compared to just 19% on placebo.
- The positive results position Silence Therapeutics to potentially compete with a similar drug from Takeda Pharmaceuticals that is nearing approval.
